“…For clinical data, this includes new clinical drug studies, 62–69 comparison of different measurement algorithms, 70–73 improved heart rate assessment correction, 74 and multiple studies from independent groups re‐analyzing the FDA clinical trial data 70,71,75,76 . For nonclinical studies, this includes drugs overlapping with clinical study drugs and many interesting drugs without clinical data 35,77–82 . For example, a recent nonclinical in vivo study focused on vanoxerine, 80 an interesting drug with large QTc prolongation that has multi‐ion channel effects, and was hypothesized by a sponsor to be of relatively low risk for TdP 83 .…”